Response to the Letter “Clarifying Postpartum Renal Risk After Hemolysis, Elevated Liver Enzymes, and Low Platelet Count Syndrome” Authors: Jean-Michel Halimi, Grégory Lailler, Valentin Maisons, Bénédicte Sautenet, Laurent Faucher, Jean-Baptiste de Fréminville, Jacques Blacher, Valérie Olié Published: 2026 The Author Replies: We thank Yi et al.1 from the Department of Acupuncture, Guangzhou University, China, for their interest and positive comments.2 One of our main objectives was to study, using real-world data, maternal characteristics associated with isolated pre-eclampsia and pre-eclampsia with hemolysis, elevated liver enzymes, and low platelet count (HELLP syndrome and/or pre-eclampsia (PE)-HELLP). We therefore selected all eligible pregnant women, including those with pre-existing conditions like pre-existing chronic kidney disease (CKD). Documented pre-existing CKD was uncommon (0.35% in isolated pre-eclampsia and 0.20% in pre-eclampsia with HELLP syndrome). As acknowledged in our article, CKD ascertainment in the Système National des Données de Santé is incomplete and predominantly captures more severe disease. Consequently, excluding only women with identified CKD would not have excluded all pre-existing CKD and could have introduced misclassification bias. Moreover, at 6 to 8 weeks after hypertensive disorders of pregnancy, CKD defined by GFR < 60 ml/min per 1.73 m2 is rare.1,3 We agree that our first follow-up period would be more precisely described in the results as extending from 6 weeks to 1 year after delivery, as already specified in the methods. Events occurring between hospital discharge and 6 weeks postpartum were not included in this analysis. This was intentional, as the first 6 weeks were considered the immediate postpartum period. Our estimates should therefore be interpreted as applying to the period from 6 weeks to 1 year postpartum, rather than to the entire first postpartum year. We thank Yi et al.1 who pinpointed this issue. Finally, our primary objective was to provide clinically interpretable estimates of subsequent risk for women presenting with either disorder. Using pregnancies without PE as the common reference allowed us to quantify the magnitude of risk associated with a history of isolated PE or PE-HELLP. A direct comparison between PE-HELLP and isolated PE would address a different question—the relative risk of 1 disorder compared with the other—rather than quantifying the excess risk associated with each disorder relative to an unaffected pregnancy. This clinical perspective guided our choice of model and reference group. Of note, the hazard ratios that we used were not separated—they were calculated from the same model with a variable with 3 categories. Therefore, our comparisons were valid.